Studies pancreatic tumors in people with von Hippel-Lindau disease
Tests a PET scan using 68-Gallium DOTATATE to find pancreatic tumors in people with VHL.
Plain-language title generated from the registry record
Registry title: Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Key facts
- Where
- Bethesda, United StatesSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 and older with von Hippel-Lindau (VHL) disease who have at least one pancreas problem seen on a scan, such as a cyst or a solid lesion.
- Age
- 12 years and older
- Sex
- All sexes can join
- Disease stage
- VHL disease with at least 1 pancreas problem on a non-invasive scan: a cyst, a solid lesion suspicious for microcystic adenoma, a solid enhancing lesion suspicious for PNET, or any other solid pancreas lesion.
- Biomarker or test result
- VHL confirmed by a gene test showing a heterozygous germline pathogenic variant in VHL, or by clinical criteria.
Main reasons for not taking part
- People who cannot have repeated non-invasive imaging scans cannot join.
Read by machine on 9 November 2026.
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Cancer Institute (NCI)
- Trial code
- NCT04074135
- Record updated
- 16 October 2026
- Original description
Background:Read full original descriptionShow less
Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Background:
People with von Hippel-Lindau (VHL) can have problems with a variety of organs, such as the pancreas. The disease can cause tumors of the pancreas. This can result in life-threatening complications. Researchers want to learn more about these pancreatic tumors and how to better detect them. This may help them design better future treatment and care for people with VHL disease.
Objective:
To better understand VHL disease that affects the pancreas and to test whether adding a certain type of scan (68-Gallium DOTATATE PET/CT) can further detect tumors.
Eligibility:
People ages 12 and older with VHL that causes tumors and cysts to grow in the pancreas
Design:
Participants will be screened with their medical records and imaging studies.
Participants will have an initial evaluation:
Participants will have their body examined by different doctors. This will depend on what types of symptoms they have.
Participants will have blood and urine tests
Participants will have images made of their body using one or more machines: They made have a CT or PET/CT scan in which they lie on a table that moves through a big ring. They may have an MRI in which they lie on a table that moves into a big tube. They may have an ultrasound that uses a small stick that produces sound waves to look at the body.
After the first visit, participants will be asked to return to the NIH. Some of the tests performed at the first visit will be repeated. Depending on their disease status, visits will be once a year or every 2 years for life.
Exclusion: Inability of participant to undergo serial non-invasive imaging.
INCLUSION CRITIERIA:; Participants who have been diagnosed with VHL using the following criteria:; -- Identification of a heterozygous germline pathogenic variant in VHL by molecular genetic testing; or; -- Clinical criteria; Participants with at least 1 pancreatic manifestation of VHL as documented on any non-invasive imaging study. These manifestations may include:; Pancreatic cyst(s); Solid lesions suspicious for microcystic adenoma(s); Solid enhancing lesions suspicious for PNET(s); Any other solid lesion(s) of the pancreas; Age greater than or equal to 12 years; Ability of participant to understand and the willingness to sign a written informed consent document.